Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
Tanya GuptaNatasha PuringtonMina LiuSummer HanGeorge SledgeLidia SchapiraAllison W KurianPublished in: Breast cancer research and treatment (2022)
In a diverse, multi-institutional, contemporary breast cancer cohort, the only incident comorbidity that differed between ET options was osteoporosis, a known side effect of AIs. These results may inform clinical decision-making about ET, and reassure patients who have bothersome symptoms on AIs that they are unlikely to develop worse comorbidities if they switch to tamoxifen.
Keyphrases
- decision making
- end stage renal disease
- cardiovascular disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- estrogen receptor
- postmenopausal women
- prognostic factors
- positive breast cancer
- bone mineral density
- type diabetes
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- physical activity
- patient reported
- sleep quality
- cell therapy